Huang Minzhao, Tang Su-Ni, Upadhyay Ghanshyam, Marsh Justin L, Jackman Christopher P, Srivastava Rakesh K, Shankar Sharmila
Department of Pharmacology, Toxicology and Therapeutics, and Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Department of Biochemistry, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA.
Cancer Lett. 2014 Oct 10;353(1):32-40. doi: 10.1016/j.canlet.2014.06.021. Epub 2014 Jul 19.
The purpose of the study was to examine the molecular mechanisms by which rottlerin inhibited growth of human pancreatic tumors in Balb C nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. AsPC-1 cells were injected subcutaneously into Balb c nude mice, and tumor-bearing mice were treated with rottlerin. Cell proliferation and apoptosis were measured by Ki67 and TUNEL staining, respectively. The expression of components of Akt, Notch, and Sonic Hedgehog (Shh) pathways were measured by the immunohistochemistry, Western blot analysis, and/or q-RT-PCR. The effects of rottlerin on pancreatic cancer cells isolated from Kras(G12D) mice were also examined. Rottlerin-treated mice showed a significant inhibition in tumor growth which was associated with suppression of cell proliferation, activation of capase-3 and cleavage of PARP. Rottlerin inhibited the expression of Bcl-2, cyclin D1, CDK2 and CDK6, and induced the expression of Bax in tumor tissues compared to untreated control. Rottlerin inhibited the markers of angiogenesis (Cox-2, VEGF, VEGFR, and IL-8), and metastasis (MMP-2 and MMP-9), thus blocking production of tumorigenic mediators in tumor microenvironment. Rottlerin also inhibited epithelial-mesenchymal transition by up-regulating E-cadherin and inhibiting the expression of Slug and Snail. Furthermore, rottlerin treatment of xenografted tumors or pancreatic cancer cells isolated from Kras(G12D) mice showed a significant inhibition in Akt, Shh and Notch pathways compared to control groups. These data suggest that rottlerin can inhibit pancreatic cancer growth by suppressing multiple signaling pathways which are constitutively active in pancreatic cancer. Taken together, our data show that the rottlerin induces apoptosis and inhibits pancreatic cancer growth by targeting Akt, Notch and Shh signaling pathways, and provide a new therapeutic approach with translational potential for humans.
本研究的目的是探讨rottlerin抑制Balb C裸鼠体内人胰腺肿瘤生长以及从Kras(G12D)小鼠分离的胰腺癌细胞生长的分子机制。将AsPC-1细胞皮下注射到Balb c裸鼠体内,对荷瘤小鼠用rottlerin进行治疗。分别通过Ki67和TUNEL染色检测细胞增殖和凋亡。通过免疫组织化学、蛋白质印迹分析和/或定量逆转录聚合酶链反应检测Akt、Notch和Sonic Hedgehog (Shh)信号通路各组分的表达。还检测了rottlerin对从Kras(G12D)小鼠分离的胰腺癌细胞的作用。用rottlerin治疗的小鼠肿瘤生长受到显著抑制,这与细胞增殖受抑制、caspase-3激活和PARP裂解有关。与未处理的对照组相比,rottlerin抑制肿瘤组织中Bcl-2、细胞周期蛋白D1、细胞周期蛋白依赖性激酶2 (CDK2)和细胞周期蛋白依赖性激酶6 (CDK6)的表达,并诱导Bax的表达。rottlerin抑制血管生成标志物(环氧合酶-2 (Cox-2)、血管内皮生长因子(VEGF)、血管内皮生长因子受体(VEGFR)和白细胞介素-8 (IL-8))以及转移标志物(基质金属蛋白酶-2 (MMP-2)和基质金属蛋白酶-9 (MMP-9)),从而阻断肿瘤微环境中致瘤介质的产生。rottlerin还通过上调E-钙黏蛋白并抑制Slug和Snail的表达来抑制上皮-间质转化。此外,与对照组相比,用rottlerin处理异种移植肿瘤或从Kras(G12D)小鼠分离的胰腺癌细胞时,Akt、Shh和Notch信号通路受到显著抑制。这些数据表明,rottlerin可通过抑制胰腺癌中组成性激活的多种信号通路来抑制胰腺癌生长。综上所述,我们的数据表明,rottlerin通过靶向Akt、Notch和Shh信号通路诱导凋亡并抑制胰腺癌生长,并为人类提供了一种具有转化潜力的新治疗方法。